Harmonisation framework for health based evaluation of indoor emissions from construction products in the European Union using the EU-LCI concept

This report describes a harmonised procedure for establishing a list of compounds and their associated LCI (Lowest Concentration of Interest) values for the evaluation of emissions from construction products taking into account existing procedures used in some Member States (i.e. ANSES in France and AgBB in Germany). It provides an appropriate health‐protective, science-based and transparent yet pragmatic approach with a flexible framework that enables review of the procedure to take into account new knowledge (e.g. data resulting from the REACH implementation process) for future revision of the EU-LCI master list in terms of both the compounds listed and their EU-LCI values.JRC.I.1-Chemical Assessment and Testin

French feedback from urban soil geochemical data archive to data sharing: state of mind and intent

International audienceUrban territories collect many types of geochemical and physico-chemical data relative to, e.g., soil quality or soil functions. Such data may serve for various purposes like verifying the compatibility with current or future uses, defining (pedo)geochemical backgrounds, establishing levels of exposure to soil pollutants, identifying management options for polluted sites or for excavated soils, verifying the evolution of infiltration ponds, assessing carbon storage, etc. They may also serve to prioritize soil functions and associated ecosystem services such as, e.g., soil fertility, surface and groundwater storage or supply, purification of infiltrated rainwater, etc. Gathering such data in national databases and making them available to stakeholders raises many issues that are technical, legal and social. Should all of the data be made available or only selected portions? How can access and reuse of the data be ensured in a legal fashion? Are statistical and geostatistical methods able to deal with data from heterogeneous origins, allowing their reuse for other purposes than the initial one? In this context, it is necessary to take into account scientific as well as practical considerations and to collect the societal needs of end-users like urban planners. To illustrate the complexity of these issues and ways to address them, we propose to share the French experience: •on gathering urban soil geochemical data in the French national database BDSolU. We will present how this database was created, the choices made in relation with the national context, the difficulties encountered, and the questions that are still open. •on a new interrogation system linking agricultural and urban soil databases (DoneSol and BDSolU), which have different requirements, and the corresponding standards. Such linkage based on interoperability is important in the context of changes of soil use, with for example agricultural soils becoming urbanised soils, or soils from brownfields intended for gardening. It is also necessary to ensure a territorial continuity for users. The objective is to define a robust and standardised methodology for database conceptualisation, sharing and final use by stakeholders including scientist

Nefopam Pharmacokinetics in Patients with End-Stage Renal Disease

International audienc

Effect of Geogenic Lead on Fungal and Collembolan Communities in Garden Topsoil

Geogenic lead (Pb) is considered to be less bioavailable than anthropogenic Pb and exerts less effect on the soil fauna. However, Pb contamination in vegetables has been reported in the case of geogenic anomalies, even at moderate concentrations (around 170 mg kg-1). In this study, we investigated collembolan communities using both taxonomic-and trait-based approaches and observed fungal communities to assess the effects of a moderate geogenic Pb anomaly on collembolans and fungi in an urban vegetable garden soil. Results indicated that geogenic Pb indeed modified fungi communities and altered the functional structure of collembolan communities in garden soils. Although geogenic Pb presented low bioavailability, it affected soil fauna and vegetables similar to anthropogenic Pb

Performance of rapid diagnostic tests for imported malaria in clinical practice: results of a national multicenter study.

We compared the performance of four rapid diagnostic tests (RDTs) for imported malaria, and particularly Plasmodium falciparum infection, using thick and thin blood smears as the gold standard. All the tests are designed to detect at least one protein specific to P. falciparum (Plasmodium histidine-rich protein 2 (PfHRP2) or Plasmodium LDH (PfLDH)) and one pan-Plasmodium protein (aldolase or Plasmodium LDH (pLDH)). 1,311 consecutive patients presenting to 9 French hospitals with suspected malaria were included in this prospective study between April 2006 and September 2008. Blood smears revealed malaria parasites in 374 cases (29%). For the diagnosis of P. falciparum infection, the three tests detecting PfHRP2 showed high and similar sensitivity (96%), positive predictive value (PPV) (90%) and negative predictive value (NPV) (98%). The PfLDH test showed lower sensitivity (83%) and NPV (80%), despite good PPV (98%). For the diagnosis of non-falciparum species, the PPV and NPV of tests targeting pLDH or aldolase were 94-99% and 52-64%, respectively. PfHRP2-based RDTs are thus an acceptable alternative to routine microscopy for diagnosing P. falciparum malaria. However, as malaria may be misdiagnosed with RDTs, all negative results must be confirmed by the reference diagnostic method when clinical, biological or other factors are highly suggestive of malaria

Médias et villes (XVIIIe-XXe siècle)

Comment les médias (presse, radio, télévision) se sont-ils adaptés aux transformations des villes depuis plus de deux siècles ? Comment s'y sont-ils implantés, ont-ils contribué au rayonnement des villes et à définir les contours de l'espace qu'elles dominent ? Quels furent et quels sont encore les relations entre les journalistes et les pouvoirs urbains ? La complaisance des premiers à l'égard des seconds, tentés par le contrôle de l'information locale à des fins de propagande ou de communication, relève-t-elle du cliché ou est-elle fondée ? Telles sont quelques unes des questions posées par cet ouvrage qui s'applique à saisir le rôle des médias dans la construction des identités urbaines, en France, de la seconde moitié du xviiie siècle à nos jours. Au carrefour de deux domaines de recherche en plein renouvellement, ce livre associe à la réflexion d'historiens modernistes et contemporanéistes, l'analyse de spécialistes d'autres sciences humaines (sociologie, politologie, information et communication). Il dégage, au total, de vastes champs d'études et met en perspective des interrogations que brouille parfois une actualité trop brûlante

Tolerance and efficacy of rituximab in primary Sjögren syndrome (TEARS): results of the randomized controlled trial.

International audienc

Treatment of primary Sjögren syndrome with rituximab: a randomized trial.

International audienceBACKGROUND: Primary Sjögren syndrome (pSS) is an autoimmune disorder characterized by ocular and oral dryness or systemic manifestations. OBJECTIVE: To evaluate efficacy and harms of rituximab in adults with recent-onset or systemic pSS. DESIGN: Randomized, placebo-controlled, parallel-group trial conducted between March 2008 and January 2011. Study personnel (except pharmacists), investigators, and patients were blinded to treatment group. (ClinicalTrials.gov: NCT00740948). SETTING: 14 university hospitals in France. PATIENTS: 120 patients with scores of 50 mm or greater on at least 2 of 4 visual analogue scales (VASs) (global disease, pain, fatigue, and dryness) and recent-onset (< 10 years) biologically active or systemic pSS. INTERVENTION: Randomization (1:1 ratio) to rituximab (1 g at weeks 0 and 2) or placebo. MEASUREMENTS: Primary end point was improvement of at least 30 mm in 2 of 4 VASs by week 24. RESULTS: No significant difference between groups in the primary end point was found (difference, 1.0% [95% CI, -16.7% to 18.7%]). The proportion of patients with at least 30-mm decreases in at least two of the four VAS scores was higher in the rituximab group at week 6 (22.4% vs. 9.1%; P = 0.036). An improvement of at least 30 mm in VAS fatigue score was more common with rituximab at weeks 6 (P < 0.001) and 16 (P = 0.012), and improvement in fatigue from baseline to week 24 was greater with rituximab. Adverse events were similar between groups except for a higher rate of infusion reactions with rituximab. LIMITATION: Low disease activity at baseline and a primary outcome that may have been insensitive to detect clinically important changes. CONCLUSION: Rituximab did not alleviate symptoms or disease activity in patients with pSS at week 24, although it alleviated some symptoms at earlier time points

Severe Health-Related Quality of Life Impairment in Active Primary Sjögren's Syndrome and Patient-Reported Outcomes: Data From a Large Therapeutic Trial

International audienc

Flow diagram.

<p>Flow diagram.</p